A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants

NCT04816513 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Ustekinumab

Sponsor

Janssen Research & Development, LLC